Stock Screener App

Frei -

Drug Manufacturers - Specialty & Generic

1.75

8.62% -0.16

Esperion Therapeutics Inc (ESPR)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt ESPR? Forum Prognose Aktiensplit

Esperion Therapeutics Inc Aktie (ESPR) Neueste Nachrichten

Why Is Esperion Therapeutics (ESPR) Down 3.9% Since Last Earnings Report? - Yahoo Finance

Esperion Therapeutics (NASDAQ:ESPR) Rating Lowered to Hold at StockNews.com - MarketBeat

Esperion Gets FDA Phase III Go-Ahead Without CVOT - Scrip

Esperion to Participate in Upcoming 2024 Cantor Global Healthcare Conference - GlobeNewswire

Esperion to Participate in Upcoming 2024 Cantor Global Healthcare Conference - StockTitan

Esperion Secures Additional Commercial and Medicare - GlobeNewswire

Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) - StockTitan

StockNews.com Downgrades Esperion Therapeutics (NASDAQ:ESPR) to Hold - MarketBeat

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Short Interest Update - MarketBeat

Weekly Investment Analysts’ Ratings Changes for Esperion Therapeutics (ESPR) - Defense World

Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire

Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference - Yahoo Finance

Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference - StockTitan

Esperion Therapeutics (NASDAQ:ESPR) Upgraded at StockNews.com - Defense World

Esperion Therapeutics (NASDAQ:ESPR) Upgraded to Buy by StockNews.com - MarketBeat

Update: Lawsuit for Investors in shares of Esperion Therapeutics, Inc. (NASDAQ: ESPR) announced by Shareholders Foundation - Newswire

Esperion Therapeutics' chief commercial officer sells shares worth $410 - Investing.com

Esperion Therapeutics' chief commercial officer sells shares worth $410 By Investing.com - Investing.com UK

Esperion Therapeutics: Delivering On Expectations While Navigating Overhangs (NASDAQ:ESPR) - Seeking Alpha

Esperion Therapeutics: Strategically Positioned To Grow - Seeking Alpha

Equities Analysts Issue Forecasts for Esperion Therapeutics, Inc.'s Q3 2024 Earnings (NASDAQ:ESPR) - MarketBeat

Esperion Therapeutics (NASDAQ:ESPR) Downgraded to Hold at StockNews.com - Defense World

Q3 2024 EPS Estimates for Esperion Therapeutics, Inc. (NASDAQ:ESPR) Reduced by HC Wainwright - Defense World

19th Annual Cardiometabolic Health Congress: Honoring the Life and Legacy of CMHC Co-Chair Dr. George L. Bakris - GlobeNewswire Inc.

Needham & Company LLC Cuts Esperion Therapeutics (NASDAQ:ESPR) Price Target to $6.00 - MarketBeat

Earnings call: Esperion reports strong Q2 growth with cardiovascular therapies - Investing.com Australia

Esperion Therapeutics (NASDAQ:ESPR) Price Target Cut to $6.00 by Analysts at Needham & Company LLC - Defense World

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q2 2024 Earnings Call Transcript - Insider Monkey

Esperion Therapeutics (NASDAQ:ESPR) Receives Buy Rating from HC Wainwright - Defense World

Earnings call: Esperion reports strong Q2 growth with cardiovascular therapies - Investing.com Canada

Earnings call: Esperion reports strong Q2 growth with cardiovascular therapies - Investing.com India

Earnings call: Esperion reports strong Q2 growth with cardiovascular therapies - Investing.com

Earnings call: Esperion reports strong Q2 growth with cardiovascular therapies - Investing.com UK

Esperion Therapeutics: Q2 Earnings Snapshot - San Antonio Express-News

Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates - MSN

Esperion Therapeutics: Q2 Earnings Snapshot - New Haven Register

Esperion Therapeutics, Inc. (ESPR) Q2 2024 Earnings Call Transcript - Seeking Alpha

Esperion Therapeutics (NASDAQ:ESPR) Stock Rating Reaffirmed by HC Wainwright - MarketBeat

Esperion Therapeutics: Q2 Earnings Snapshot - The Washington Post

Esperion's (ESPR) Q2 Loss Narrows, Revenues Soar Year Over Year - Yahoo Finance

ESPR Stock Earnings: Esperion Therapeutics Beats EPS, Beats Revenue for Q2 2024 - InvestorPlace

Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update - GlobeNewswire

Ann Arbor drugmaker finishes Q2 in the red despite sales increase - Crain's Detroit Business

Esperion Therapeutics Shares Fall on Wider-Than-Expected 2Q Loss - MarketWatch

Esperion Therapeutics: Q2 Earnings Snapshot - CTPost

Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance

Esperion Therapeutics: Q2 Earnings Snapshot - Barchart

Earnings summary: Esperion Therapeutics reports mixed Q2 results; reaffirms FY24 outlook - Seeking Alpha

Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update - StockTitan

Vanguard Group Inc. Raises Holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - MarketBeat

Vanguard Group Inc. Raises Stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Defense World

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - StockTitan

Esperion announces CMO transition with severance package - Investing.com India

Ratios Uncovered: Breaking Down Esperion Therapeutics Inc. (ESPR)’s Trailing Twelve Months Metrics - The Dwinnex

Esperion announces CMO transition with severance package - Investing.com

Esperion Announces CMO Transition and Continued Advisory Role - TipRanks

Esperion Therapeutics (ESPR) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance Australia

Esperion Therapeutics (ESPR) to Release Earnings on Monday - MarketBeat

Esperion Therapeutics (ESPR) Scheduled to Post Earnings on Monday - Defense World

Esperion Therapeutics, Inc. to Post Q2 2024 Earnings of ($0.21) Per Share, Zacks Research Forecasts (NASDAQ:ESPR) - MarketBeat

Q2 2024 EPS Estimates for Esperion Therapeutics, Inc. (NASDAQ:ESPR) Raised by Analyst - Defense World

Esperion Therapeutics, Inc. Announces Exercise of Underwriters' Over-Allotment Option for Initial Pu - AOL

Esperion Therapeutics, Inc. Expected to Earn Q4 2025 Earnings of $0.17 Per Share (NASDAQ:ESPR) - Defense World

$106.87

1.10%

$75.50

0.23%

$60.11

0.87%

$122.89

0.45%

$79.70

0.87%

$11.77

0.90%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | Open in MarketWatch | Open in EDGAR | Open in Reuters